Litigation Details for AMGEN INC. v. APOTEX INC. (D.N.J. 2022)
✉ Email this page to a colleague
AMGEN INC. v. APOTEX INC. (D.N.J. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-06-14 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 10,092,541; 7,427,638; 9,872,854 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AMGEN INC. v. APOTEX INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for AMGEN INC. v. APOTEX INC. (D.N.J. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-06-14 | 1 | Complaint | States Patent Nos. 7,427,638 (“the ’638 Patent”), 9,872,854 (“the ’854 Patent”), and 10,092,541 (“the …Celgene asserted the ’638 Patent, ’854 Patent, and ’541 Patent, among other patents listed in the Orange … Amgen asserted five patents at trial, including the ’638 Patent and ’541 Patent. Specifically, Amgen… This is a civil action for patent infringement arising under the patent laws of the United States, …the ’541 Patent”) (collectively, “the Patents-in-Suit”). THE | External link to document |
| 2023-01-22 | 39 | Stipulation and Order | the term “Patents-in-Suit” shall mean U.S. Patent Nos. 7,427,638, 9,872,854, and 10,092,541. Case 3:22…Apotex ANDA and the Apotex ANDA Product, that the Patents-In-Suit are valid and enforceable. …Apotex ANDA and the Apotex ANDA Product, that the Patents-In-Suit would be infringed by making, using, offering… 7. Until expiration of the Patents-in-Suit, including all extensions and pediatric…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any Affiliate | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
